ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA106 – SLP therapeutic for COVID-19